Outlook Therapeutics Inc (OTLK)

Jun 13, 2025

Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 13, 2025

Jun 13, 2025

Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com India

Jun 13, 2025

Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - marketscreener.com

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in S - GuruFocus

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of - GlobeNewswire

Jun 10, 2025

Jun 10, 2025

Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients - Stock Titan

Jun 10, 2025

Jun 10, 2025

Jane Street Group LLC Purchases 15,008 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jun 10, 2025

Jun 06, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 06, 2025

Jun 06, 2025

Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 - Investing.com Australia

Jun 06, 2025

Jun 06, 2025

Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 By Investing.com - Investing.com South Africa

Jun 06, 2025

Jun 06, 2025

Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Mai - GuruFocus

Jun 06, 2025

Jun 06, 2025

Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Maintains Buy Rating | OTLK Stock News - GuruFocus

Jun 06, 2025

Jun 04, 2025

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.

Jun 04, 2025

Jun 03, 2025

Northern Trust Corp Sells 7,119 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jun 03, 2025

Jun 03, 2025

Outlook Therapeutics launches LYTENAVA in Germany and UK By Investing.com - Investing.com South Africa

Jun 03, 2025

Jun 02, 2025

Outlook Therapeutics® Announces Commercial Launch of - GlobeNewswire

Jun 02, 2025

Jun 02, 2025

Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD - marketscreener.com

Jun 02, 2025

Jun 02, 2025

Outlook Therapeutics (OTLK) Launches LYTENAVA in European Markets | OTLK Stock News - GuruFocus

Jun 02, 2025

Jun 02, 2025

Outlook Therapeutics launches LYTENAVA in Germany and UK - Investing.com Australia

Jun 02, 2025

Jun 02, 2025

Outlook Therapeutics Launches LYTENAVA For Patients With Wet AMD In Germany And The UK - Nasdaq

Jun 02, 2025

Jun 02, 2025

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - The Manila Times

Jun 02, 2025

May 31, 2025

Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst - Defense World

May 31, 2025

May 30, 2025

Brokers Issue Forecasts for OTLK FY2026 Earnings - Defense World

May 30, 2025

May 28, 2025

Metric Analysis: Outlook Therapeutics Inc (OTLK)’s Key Ratios in the Limelight - DWinneX

May 28, 2025

May 25, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Average Target Price from Brokerages - Defense World

May 25, 2025

May 23, 2025

Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks

May 23, 2025

May 23, 2025

Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus

May 23, 2025

May 23, 2025

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus

May 23, 2025

May 23, 2025

Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus

May 23, 2025

May 23, 2025

Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering - marketscreener.com

May 23, 2025

May 23, 2025

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

May 23, 2025

May 23, 2025

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan

May 23, 2025

May 23, 2025

Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus

May 23, 2025

May 23, 2025

Outlook Therapeutics Reports Improved Financials Amid Challenges - TipRanks

May 23, 2025

May 22, 2025

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours - marketscreener.com

May 22, 2025

May 22, 2025

Outlook Therapeutics announces public stock offering - Investing.com Australia

May 22, 2025

May 22, 2025

Outlook Therapeutics announces public stock offering By Investing.com - Investing.com Canada

May 22, 2025

May 22, 2025

Outlook Therapeutics (OTLK) Launches Public Offering of Stock and Warrants | OTLK Stock News - GuruFocus

May 22, 2025

May 22, 2025

Outlook Therapeutics® Announces Proposed Public Offering of Comm - GuruFocus

May 22, 2025

May 22, 2025

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News - GuruFocus

May 22, 2025

May 22, 2025

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - The Manila Times

May 22, 2025

May 22, 2025

Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Nasdaq

May 22, 2025

May 20, 2025

Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News - GuruFocus

May 20, 2025

May 17, 2025

Outlook Therapeutics (NASDAQ:OTLK) vs. Novavax (NASDAQ:NVAX) Head-To-Head Survey - Defense World

May 17, 2025

May 16, 2025

Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks

May 16, 2025